Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression
Citation
- Verified title: Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression
- Publication year: 2024
- DOI: 10.1038/s41467-024-54174-5
- Metadata source: crossref-doi (confidence: high)
- Original local title: Mechanics-activated fibroblasts promote pulmonary group 2 innate lymphoid cell plasticity propelling silicosis progression
Ingest Mode
- Mode:
focused manual crystallization mode - Meaning: this source page was upgraded during focused manual crystallization batch 3 and can support durable synthesis when claims stay source-linked.
- Required boundary: preserve species, tissue, assay, model, perturbation, and confidence labels when reusing claims.
Source Type
- primary pulmonary fibrosis/silicosis mechanism study
- crystallization status: manually promoted into focused manual crystallization batch 3
- Batch 3 axis: mechanics-activated fibroblast IL-18 drives ILC2 plasticity in silicosis
Evidence Profile
- Overall confidence: medium-high to high for the source-specific claims listed below; lower for broad extrapolation beyond the reported system.
- Evidence profile: mechanics-activated fibroblasts, Notch3/caspase-1/IL-18 axis, ILC2-to-ILC1 conversion, pulmonary fibrosis progression.
- Batch 3 synthesis role: mechanics-activated fibroblast IL-18 drives ILC2 plasticity in silicosis.
Why It Matters Here
This source expands lung ILC2 plasticity beyond asthma and COPD into fibrotic mechanical-niche remodeling.
Key Findings
- The source reports that ILC2 conversion to ILC1s is involved in silicosis progression.
- Mechanics-activated fibroblasts promote this conversion through IL-18 in the reported system.
- Fibroblast Notch3/caspase-1 activity is linked to IL-18 production and pulmonary fibrosis progression.
- The source strengthens the idea that stromal mechanics can reprogram lung ILC identity.
Claim-Level Confidence
- High confidence: the source supports a fibroblast-mechanics-IL-18 axis that promotes ILC2-to-ILC1-like plasticity in silicosis models.
- Medium-high confidence: this is highly relevant to pulmonary fibrosis biology, but should not be merged with allergic asthma ILC2 mechanisms without labeling disease context.
- Low confidence: human silicosis therapeutic claims require independent validation.
Methods and Context
- Source kind inferred from title/tags/text: primary research article with animal-model evidence.
- Species or sample frame detected: mouse
- Tissue or disease context detected: lung/airway, ARDS/lung injury
- Assay modalities detected from tags: flow cytometry, in vivo model, in vitro assay, genetic or knockout perturbation
- Use this source page as a knowledge-oriented first pass; confirm experimental design, gating, perturbation, and outcome measures before manuscript-level use.
Caveats
- This batch crystallization used source text and extracted article context to promote source-specific claims, but detailed figure panels should still be checked before manuscript-level quotation.
- Preserve disease, tissue, species, and assay boundaries when reusing this source.
- Do not use this source alone to make broad pan-ILC, pan-asthma, or clinical-treatment claims.
Contradiction and Supersession
- Contradiction status: not assessed during bulk ingestion.
- Supersession status: not assessed during bulk ingestion.
Related Pages
- ILC2
- ILC2 regulation
- ILC2 disease
- Lung ILC Disease Roles Companion
- Lung ILC Core Evidence Synthesis
- Focused manual crystallization batch 3 audit